跳至主要内容
临床试验/NCT02503527
NCT02503527终止不适用

Effects of a Diabetes-specific Tube Feed on Glycemic Variability in Critically Ill Patients During Insulin Blood Glucose Management

Fresenius Kabi2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2015年8月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
28
试验地点
2
主要终点
Blood glucose variability (within patient standard deviation of blood glucose values per day)

研究概览

简要总结

The purpose of this study is to determine the efficacy and safety of a diabetes-specific tube feed in comparison to an isocaloric, isonitrogenous standard enteral formula in critically ill patients receiving insulin treatment for blood glucose management.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with spontaneous aneurysmal subarachnoid hemorrhage (SAH) defined according to Hunt and Hess scale grade HH5
  • Requiring mechanical ventilation in the ICU at the time of enrolment
  • Enteral nutrition (EN) in the ICU at time of enrolment
  • If enrolment on day 3 of ICU stay, EN equal to or larger than 80% of total calories in case of supplementary parenteral nutrition (PN) with anticipated 100% EN as of day 4 to 8 of ICU stay
  • If enrolment on day 4 of ICU stay, 100% EN planned for at least 5 days from the time of enrolment
  • Patients expected to stay in the ICU for at least 5 days following enrolment
  • Age 18 - 75 years
  • Glycemic control with intravenous insulin therapy to maintain a target glucose range between 110 mg/dL and 150 mg/dL (6.1 and 8.3 mmol/l)
  • Informed consent according to local regulations for decisionally impaired subjects

排除标准

  • Patients with septic shock at time of enrolment
  • Participation in a clinical trial with any investigational product within 4 weeks before study
  • Patients requiring a fibre free diet
  • Total or supplementary parenteral nutrition (> 20% of total calories)
  • Known or suspected intolerance or allergy to any component of the study product(s), e.g. galactosemia
  • Gastrectomy
  • Postpyloric nutrition
  • Any clinical condition not allowing enteral nutrition (e.g. emesis, severe reflux, severe diarrhea)
  • Known severe heart failure (NYHA class 4)
  • Liver insufficiency / failure (male: ALAT > 150 U/l; female: ALAT > 120 U/l)
  • Acute kidney failure (blood creatinine > 2.5 mg/dl)
  • Body Mass Index < 18 or > 35 kg/m²
  • Known or suspicion of drug abuse
  • Pregnant or breast feeding women
  • Patients with diabetes mellitus type I
  • Exclusion After Enrolment (Withdrawal of Subjects)
  • Start of PN with more than 20% of total given energy amount/ day
  • Insulin infusion stopped unexpectedly for > 12h for non-nutritional reasons
  • Discharge from ICU
  • Intolerable AEs
  • Major protocol violation
  • Withdrawal of informed consent
  • Discontinuation of study treatment for other reasons

结局指标

主要结局

Blood glucose variability (within patient standard deviation of blood glucose values per day)

时间窗: At Day 3 of intervention or the day prior to switch from intravenous to subcutaneous insulin administration, whichever comes first

次要结局

  • ICU mortality(Day 28)
  • ICU length of stay(Day 28)
  • Glucose variability(Days 2, 4 and 5 of intervention)
  • Time to switch from intravenous to subcutaneous insulin administration(Days 1-6, daily)
  • Insulin requirements in IU per day(Days 1 - 6, daily)
  • Blood glucose levels(Days 1 - 6, daily)
  • HbA1c(Days 1, 6, 28)
  • Difference between target and given enteral nutrition (Compliance)(Days 2-6, daily)
  • Cerebral and subcutaneous microdialysis: glucose(Days 1 - 6, daily)
  • Cerebral and subcutaneous microdialysis: lactate/pyruvate ratio(Days 1 - 6, daily)
  • Hospital mortality(Day 28)
  • Days of mechanical ventilation(Day 28)
  • Non-gastrointestinal complications (AEs) to enteral nutrition and application(Days 2-6, daily)
  • Gastro-intestinal intolerance (AEs, complications)(Days 2-6, daily)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验